A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease

Gillian Horne, Jon Stobo, Caroline Kelly, Arunima Mukhopadhyay, Anne Latif, Judith Dixon, Lynn McMahon, P Cony-Makhoul, Jenny Byrne, Graeme Smith, schafhausen Koschmieder, T BrÜmmendorf , P Schafhausen, P Gallipoli, Fiona Thomson, Wenjuan Cong, R Clark, Dragana Milojkovic, Vignir Helgason, Letizia ForoniFranck-Emmanuel NICOLINI, Tessa Holyoake, Mhairi Copland

Research output: Contribution to journalArticle (Academic Journal)peer-review

23 Citations (Scopus)
16 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease'. Together they form a unique fingerprint.

Medicine & Life Sciences